• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Akili Interactive Labs, Pfizer partner to test Alzheimer’s video game

Akili Interactive Labs, Pfizer partner to test Alzheimer’s video game

January 15, 2014
CenterWatch Staff

Akili Interactive Labs has entered into an agreement with Pfizer to test the ability of Akili’s mobile video game platform (Project EVO) to detect cognitive differences in healthy elderly people at risk of developing Alzheimer’s disease.

To Akili’s knowledge this is the first time a large pharmaceutical company will test the use of a mobile video game as a clinical tool to determine early signs of neurodegenerative disease pathology.

Pfizer will conduct a clinical trial that will evaluate healthy elderly subjects with and without the presence of amyloid in their brains, as determined by Positron Emission Tomography (PET) imaging. Approximately 100 individuals are expected to be enrolled with their cognitive abilities assessed both at baseline, and over the course of one month of game play. The goal of the trial is to investigate the Akili game as a biomarker or clinical endpoint for potential use in future Alzheimer’s trials.

The Akili video game platform is designed to quantify and improve the ability of individuals to deal with cognitive interference (distractions and interruptions), which affects their ability to pay attention, plan and make decisions. Such deficits are common symptoms of many degenerative diseases including Alzheimer’s, as well as psychiatric conditions such as ADHD, autism and depression. The underlying Akili platform technology originated from the laboratory of Adam Gazzaley, M.D., Ph.D., at the University of California, San Francisco. Gazzaley is a co-founder and chief science advisor to Akili.

“A tool that enables cognitive monitoring for the selection and assessment of clinical trial patients has the potential to be an important advance in Alzheimer’s research and beyond,” said Michael Ehlers, senior vice president and chief scientific officer of the Neuroscience Research Unit at Pfizer.

In the last year, Akili has garnered approximately $7 million in cash and non-dilutive funding equivalents, including this Pfizer collaboration and a previously undisclosed investment from and collaboration with Shire Pharmaceuticals.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing